Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Lululemon Shares Tumble as Growth Forecast Slashed

Andreas Sommer by Andreas Sommer
September 9, 2025
in Analysis, Consumer & Luxury, Earnings
0
Lululemon Stock
0
SHARES
175
VIEWS
Share on FacebookShare on Twitter

The athletic apparel retailer Lululemon, once a darling of the sector, is facing significant headwinds. A stark downward revision of its full-year guidance has rattled investor confidence, revealing deep-seated operational challenges within its crucial North American business. The announcement has prompted a critical reevaluation of the company’s near-term prospects.

Guidance Shock Triggers Sell-Off

The catalyst for the recent sharp decline was the earnings report released on September 4. While the company managed to surpass analyst profit expectations for the quarter, this achievement was entirely overshadowed by a severe cut to its annual forecast. Management slashed its 2025 revenue outlook by approximately $300 million. More dramatically, its earnings per share guidance was reduced by nearly $2.

This disappointing revision is attributed to a confluence of factors. A noticeable softening in consumer demand within the U.S. market led to a 4% drop in comparable sales for the second quarter. Furthermore, the company is grappling with substantial tariff-related headwinds. CEO Calvin McDonald conceded that the brand’s casual product assortment had become “too predictable” and was failing to resonate with shoppers. The increased tariff burdens are projected to reduce the 2025 gross profit by a significant $240 million.

Market Experts Downgrade Ratings En Masse

The financial community’s response was swift and severe. Numerous prominent banks and research firms moved to downgrade their recommendations and price targets for the stock.

Should investors sell immediately? Or is it worth buying Lululemon?

Analysts at Telsey Advisory Group removed their “Outperform” rating and drastically reduced their target from $360 to $200. Wells Fargo analysts issued a new target of $160. William Blair similarly withdrew its “Outperform” assessment. In a contrasting move, Truist Securities maintained a “Buy” recommendation with a $290 price target, standing against the prevailing negative sentiment. The overall consensus, however, is clear: the collective rating from the 29 analysts covering Lululemon has now slipped to “Hold,” indicating widespread and persistent skepticism.

International Operations Provide a Silver Lining

Amid the gloom in North America, Lululemon’s international segment continues to be a notable bright spot. The company is anticipating robust growth of 20-25% in China for 2025, with other international markets expected to expand by roughly 20%. While this geographic diversification offers a partial buffer, it is currently insufficient to fully counterbalance the pronounced struggles in the U.S. and the financial impact of tariffs.

In response to these challenges, the management team has outlined a recovery strategy. A fundamental overhaul of the product portfolio is promised, with the proportion of new styles slated to increase from 23% to 35% by the spring of 2026. The company is counting on new innovations, such as its “Align No Line” pants, to reinvigorate consumer interest and drive a recovery.

The critical question remains whether these initiatives can successfully engineer a turnaround. Forthcoming quarterly results will be scrutinized for early signs that the new strategy is gaining traction or if the current downward trend is set to continue.

Ad

Lululemon Stock: Buy or Sell?! New Lululemon Analysis from March 25 delivers the answer:

The latest Lululemon figures speak for themselves: Urgent action needed for Lululemon investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Lululemon: Buy or sell? Read more here...

Tags: Lululemon
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

March 25, 2026
Humacyte Stock
Analysis

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock
AI & Quantum Computing

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
Next Post
Lexicon Stock

Lexicon Pharmaceuticals Nears Critical Regulatory Milestone

Skyworks Stock

Leadership Shift at Skyworks Solutions Sparks Investor Interest

Cisco Stock

Cisco's AI Infrastructure Push: Strategic Moves and Market Implications

Recommended

Alphabet Stock

Alphabet Shares Face Regulatory Headwinds Despite Autonomous Driving Breakthrough

4 months ago
Dish Network Stock

Institutional Investors Show Diverging Views on Dish Network’s Future

7 months ago
Finance_ Trading ratings today (2)

Lakeland Financial Exceeds Expectations with Fourth Quarter Earnings

2 years ago
DeFi Technologies Stock

DeFi Technologies: Navigating Expansion Amidst Legal Headwinds

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Hain Celestial Sheds Snack Division in Strategic Overhaul

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

Lumen’s AI Infrastructure Push Gains Recognition Amid Strategic Overhaul

Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink

Trending

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

by Kennethcix
March 25, 2026
0

BioNano Genomics has wrapped up its fiscal year 2025, presenting a financial picture marked by significant operational...

Humacyte Stock

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Talphera Stock

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds
  • Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts
  • Evolent Health Bets on AI Leadership Amid Share Price Decline

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com